Sabin-Aspen Vaccine Science & Policy Group
The Sabin-Aspen Vaccine Science & Policy Group brings together senior leaders across many disciplines to examine some of the most challenging vaccine-related issues and drive impactful change. Members are influential, creative, out-of-the-box thinkers who vigorously probe a single topic each year and develop actionable recommendations to advance innovative ideas for the development, distribution, and use of vaccines, as well as evidence-based and cost-effective approaches to immunization.
Restructuring R&D to produce essential vaccines for infectious diseases we already recognize, and for those yet to emerge, is imperative. Powering Vaccine R&D: Opportunities for Transformation is a new report published by the Group that examines the core components of the vaccine ecosystem and finds opportunities to transform and accelerate the development of vaccines.
Meeting the Challenge of Vaccination Hesitancy (June 2020)
The end of the COVID-19 pandemic will depend on our ability to address vaccine hesitancy, one of the top 10 threats to global health, before a vaccine is put on the market. Meeting the Challenge of Vaccination Hesitancy lays out actionable steps that leaders across healthcare, research, philanthropy and technology can take to build confidence in vaccines and vaccinations.
The Sabin-Aspen Vaccine Science & Policy Group convened in 2018 to explore challenges and opportunities to develop a universal influenza vaccine. The group’s recommendations on how to overcome the scientific, financial and organizational barriers to developing a vaccine are synthesized in the report Accelerating the Development of a Universal Influenza Vaccine.